TA128 Azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia
Myelodysplastic syndromes – azacitidine: Review of Celgene’s response to the post-appeal ACD (PDF, 211KB) (December 2010)
Addendum to the September 2010 report by the Decision Support Unit (PDF, 12KB) (October 2010)
Myelodysplastic syndromes – Azacitidine: A critical appraisal of additional evidence submitted by Celgene and the MDS Foundation (PDF, 132KB) (September 2010)
Azacitidine STA Economic Model (PDF, 16KB) (September 2009)
DSU response to manufacturer’s revised model (PDF, 63KB) (December 2009)
A world top-100 university
We're a world top-100 university renowned for the excellence, impact and distinctiveness of our research-led learning and teaching.